BIOCON has invigorated its diabetics drug development drive by teaming up with US-based biopharma player Amylin Pharmaceuticals. The companies have entered into an exclusive co-development and marketing partnership for a peptide hybrid or phybrid.
Amylin Pharmaceuticals has been a front-runner in the field of peptide therapeutics and a leader in the diabetes market.
Kiran Mazumdar Shaw-led Biocon will in turn bring its recombinant knowledge, largescale manufacturing and lowcost pre-clinical and clinical development to the partnership.
"Right now the deal is a co-development deal which largely means that both Amylin and Biocon share the cost of development going forward. It is also a deal where we have marked out commercialisation territory. For example, Amylin would have the commercialisation rights in north America and Biocon would have the commercialisation rights in most parts of Asia, and in rest of the world we share jointly the commercialisation rights,” Biocon COO Arun Chandavarkar said.
The financial terms of the agreement were not disclosed.
Amylin will own the intellectual property (IP) rights to the molecule and phybrid technology while Biocon will hold the IP for manufacturing. Depending on the synergies that accrue to the companies, they could also broaden their collaboration.
Recently an application was filed under section 97 of the Central Goods and Services Tax Act, and the Maharashtra Goods and Services Tax Act, 2017 by lNA Bearing India Private Limited, being the More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More